MRX-4 was nasally administered as a single dose once a week for four consecutive weeks. The first administration was given without a nasal allergen challenge (NAC) while the subsequent three were carried out in conjunction with an NAC. The protocol was double-blinded and placebo-controlled. The company said that, during the trial, no adverse effects were observed with blood analysis and pharmacokinetic data further indicating safety.
Yuval Cohen, president of Morria, said: “We are entirely satisfied with these results. They mark an important milestone in our clinical development plan, which aims at offering a potentially safer and more effective treatment option in the multi-billion dollar allergic rhinitis market.”
Morria plans to initiate a Phase II efficacy clinical study with 175 patients, who will be treated for six days prior to allergen challenge.